DUBLIN, Ireland, September 24 /PRNewswire/ -- Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that at its Annual General Meeting today, all resolutions contained in the notice of meeting were duly passed and the results of the poll are as follows:

For* Against Withheld** 1. To elect Mr Matthew 301,376,910 4,696,170 25,441,808 Emmens as a Director of the Company 2. To elect Mr Angus 331,225,599 138,229 151,060 Russell as a Director of the Company 3. To elect Mr Graham 331,234,635 127,173 153,080 Hetherington as a Director of the Company 4. To elect Dr Barry 328,858,454 2,501,778 154,656 Price as a Director of the Company 5. To elect Mr David 330,945,634 412,470 156,784 Kappler as a Director of the Company 6. To elect Dr Jeffrey 331,221,109 138,828 154,951 Leiden as a Director of the Company 7. To elect Mr Patrick 330,949,493 412,089 153,306 Langlois as a Director of the Company 8. To elect Ms Kate 331,014,606 346,949 153,333 Nealon as a Director of the Company 9. To elect Mr David 327,884,774 2,101,928 1,528,186 Mott as a Director of the Company 10. To elect Dr Michael 331,232,603 126,815 155,470 Rosenblatt as a Director of the Company 11. To re-appoint 327,634,578 1,301,388 2,578,922 Deloitte & Touche LLP as Auditors of the Company 12. To authorise the 331,225,599 1,470,679 159,584 Audit, Compliance and Risk Committee to determine the remuneration of the Auditors 13. To authorise the 328,104,104 3,189,130 221,654 allotment of shares 14. To authorise the 329,760,418 1,575,955 178,515 disapplication of pre-emption rights 15. To authorise market 330,598,450 729,745 186,693 purchases 16. To change the name 331,323,817 31,609 159,462 of the Company to Shire plc

Notes to Editors

Shire Limited

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

For further information please contact: Investor Relations Cléa Rosenfeld (Rest of the World) +44-1256-894-160 Eric Rojas (North America) +1-484-595-8252 Media Jessica Mann (Rest of the World) +44-1256-894-280 Matthew Cabrey (North America) +1-484-595-8248 Jessica Cotrone (North America) +1-617-613-4640

For further information please contact: Investor Relations, Cléa Rosenfeld, (Rest of the World), +44-1256-894-160; Eric Rojas (North America), +1-484-595-8252. Media, Jessica Mann, (Rest of the World), +44-1256-894-280; Matthew Cabrey, (North America), +1-484-595-8248; Jessica Cotrone (North America), +1-617-613-4640